Display options
Cite
Tella SH, Kommalapati A, Correa R. Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus. 2017;9(5):e1300doi: 10.7759/cureus.1300.
Tella, S. H., Kommalapati, A., & Correa, R. (2017). Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus, 9(5), e1300. https://doi.org/10.7759/cureus.1300
Tella, Sri Harsha, et al. "Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis." Cureus vol. 9,5 (2017): e1300. doi: https://doi.org/10.7759/cureus.1300
Tella SH, Kommalapati A, Correa R. Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus. 2017 May 31;9(5):e1300. doi: 10.7759/cureus.1300. PMID: 28680788; PMCID: PMC5493470.
Copy Download .nbib Format: NLM
Share it on

Cureus. 2017 May 31;9(5):e1300. doi: 10.7759/cureus.1300.

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.

Cureus

Sri Harsha Tella, Anuhya Kommalapati, Ricardo Correa

Affiliations

  1. Endocrinology, Diabetes and Metabolism, National Institute of Health.
  2. Internal Medicine, Medstar Washington Hospital Center.
  3. NICHD, National Institute of Health.

PMID: 28680788 PMCID: PMC5493470 DOI: 10.7759/cureus.1300

Abstract

Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis. This paper reviews the profile and potential of abaloparatide in the treatment of postmenopausal osteoporosis. This paper is based on clinical trials and a PubMed search. Search terms used were "abaloparatide", "BA058", and "PTHrP". This review outlines the effects of this anabolic PTHR1 activator, which increases bone mineral density in patients at high risk for osteoporosis. The potential adverse effects of abaloparatide are also summarized. Abaloparatide has 41% homology to parathyroid hormone (PTH) (1-34) and 76% homology to parathyroid hormone-related protein (PTHrP) (1-34). The molecule was meticulously selected to retain stability and potent bone anabolic activity, and it has a limited effect on bone resorption (hence, a low calcium-mobilizing potential). Abaloparatide has shown promising results in a reduction of new onset vertebral (approximately 86% reduction) and nonvertebral fractures (approximately 43% reduction). In clinical trials to date, abaloparatide appears to have a good safety and tolerability profile with a significantly lower degree of hypercalcemia compared to that of teriparatide. Based on the clinical trials, the optimum dose of abaloparatide is 80 mcg subcutaneous once daily.

Keywords: abaloparatide; anabolic agents; bmd; osteoporosis; teriparatide

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. J Bone Miner Res. 2013 Apr;28(4):736-45 - PubMed
  2. Nat Chem Biol. 2009 Oct;5(10):734-42 - PubMed
  3. J Clin Endocrinol Metab. 2015 Feb;100(2):697-706 - PubMed
  4. N Engl J Med. 2003 Sep 25;349(13):1207-15 - PubMed
  5. Lancet. 2013 Jul 6;382(9886):50-6 - PubMed
  6. Clin Cases Miner Bone Metab. 2016 May-Aug;13(2):106-109 - PubMed
  7. J Clin Endocrinol Metab. 2014 Jul;99(7):2418-25 - PubMed
  8. J Bone Miner Res. 2017 Jan;32(1):17-23 - PubMed
  9. Endocrinology. 2016 Jan;157(1):141-9 - PubMed
  10. JAMA. 2016 Aug 16;316(7):722-33 - PubMed
  11. N Engl J Med. 2003 Sep 25;349(13):1216-26 - PubMed
  12. J Bone Miner Res. 2015 Jan;30(1):39-45 - PubMed
  13. N Engl J Med. 2001 May 10;344(19):1434-41 - PubMed
  14. Mol Endocrinol. 2008 Jan;22(1):156-66 - PubMed
  15. Calcif Tissue Int. 2016 Nov;99(5):489-499 - PubMed

Publication Types